Ameriprise’s Aratana Therapeutics, Inc. PETX Stock Holding History

Ameriprise’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,460	Closed	-$70K	–	3823
2018 Q2	$70K	Buy	+16,460	New	+$83K	﹤0.01%	3590
2015 Q2	–	Sell	-76,148	Closed	-$1.22M	–	4104
2015 Q1	$1.22M	Buy	76,148 +9,975	+15%	+$177K	﹤0.01%	2828
2014 Q4	$1.18M	Buy	66,173 +66,133	+165,333%	+$824K	﹤0.01%	2801
2014 Q3	$0	Hold	40	–	–	﹤0.01%	5952
2014 Q2	$1K	Buy	+40	New	+$567	﹤0.01%	5428

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ameriprise's PETX Position: Q3 2018 in Review

Ameriprise sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2018, closing a stake of 16,460 shares — an estimated $70K sold.

Ameriprise first reported a position in PETX in Q2 2014 and held it in 5 quarters. The position peaked at $1.22M in Q1 2015. 100 funds tracked by Wall St. Rank hold PETX as of Q3 2018.

Ameriprise reported no remaining Aratana Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Ameriprise sold 16,460 Aratana Therapeutics, Inc. shares in Q3 2018, an estimated $70K.
Ameriprise first reported a position in Aratana Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Ameriprise's Aratana Therapeutics, Inc. position peaked at $1.22M in Q1 2015.
100 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2018.

Based on Ameriprise's 13F filing for Q3 2018, filed 14 Nov 2018.